Skip to search formSkip to main contentSkip to account menu

STK33 gene

Known as: STK33, Serine/Threonine Kinase 33 Gene, SERINE/THREONINE PROTEIN KINASE 33 
This gene is involved in protein phosphorylation.
National Institutes of Health

Related topics

Related topics

5 relations
PhosphorylationSTK39 geneSerine/Threonine Kinase 33Serine/Threonine Phosphorylation

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Association of genetic polymorphisms with age at menarche in Russian women.
2018
2018
Krüppel-like Factor 4 Suppresses Serine/Threonine Kinase 33 Activation and Metastasis of Gastric Cancer through Reversing Epithelial–Mesenchymal Transition
Background: Cancers with aberrant expression of Serine/threonine kinase 33 (STK33) has been reported to be particularly… 
Highly Cited
2017
Highly Cited
2017
Afatinib Is a New Therapeutic Approach in Chordoma with a Unique Ability to Target EGFR and Brachyury
Chordomas are rare bone tumors with no approved therapy. These tumors express several activated tyrosine kinase receptors, which… 
2014
2014
STK33 promotes hepatocellular carcinoma through binding to c-Myc
Objective STK33 has been reported to play an important role in cancer cell proliferation. We investigated the role of STK33 in… 
Review
2012
Review
2012
New frontiers in promoting tumour cell death: targeting apoptosis, necroptosis and autophagy
Cancer is a multifaceted disease comprising a combination of genetic, metabolic and signalling aberrations, which severely… 
Highly Cited
2012
Highly Cited
2012
A Potent and Selective Quinoxalinone-Based STK33 Inhibitor Does Not Show Synthetic Lethality in KRAS-Dependent Cells
The KRAS oncogene is found in up to 30% of all human tumors. In 2009, RNAi experiments revealed that lowering mRNA levels of a… 
Highly Cited
2012
Highly Cited
2012
Targeting of KRAS mutant tumors by HSP90 inhibitors involves degradation of STK33
HSP90 inhibition depletes STK33 in KRAS mutant tumors. 
Highly Cited
2011
Highly Cited
2011
STK33 kinase activity is nonessential in KRAS-dependent cancer cells.
Despite the prevalence of KRAS mutations in human cancers, there remain no targeted therapies for treatment. The serine-threonine… 
Highly Cited
2010
Highly Cited
2010
Prioritization of driver mutations in pancreatic cancer using cancer-specific high-throughput annotation of somatic mutations (CHASM)
Over 20,000 genes were recently sequenced in a series of 24 pancreatic cancers. We applied CHASM (Cancer-specific High-throughput… 
2005
2005
Differential expression pattern of the novel serine/threonine kinase, STK33, in mice and men
Serine/threonine kinase 33 (STK33/Stk33) is a recently discovered gene whose inferred amino acid sequence translation displays… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)